                         SEQUENCE LISTING

<110>  Bristol-Myers Squibb Company
       
 
<120>  METHODS FOR IDENTIFYING PATIENTS AT RISK FOR COSTIMULATION 
       BLOCKADE RESISTANT REJECTION

<130>  12150-WO-PCT 

<150>  US 61/806,206
<151>  2013-03-28

<160>  2     

<170>  PatentIn version 3.5

<210>  1
<211>  1152
<212>  DNA
<213>  Artificial

<220>
<223>  L104EA29YIg

<400>  1
atgggtgtac tgctcacaca gaggacgctg ctcagtctgg tccttgcact cctgtttcca       60

agcatggcga gcatggcaat gcacgtggcc cagcctgctg tggtactggc cagcagccga      120

ggcatcgcta gctttgtgtg tgagtatgca tctccaggca aatatactga ggtccgggtg      180

acagtgcttc ggcaggctga cagccaggtg actgaagtct gtgcggcaac ctacatgatg      240

gggaatgagt tgaccttcct agatgattcc atctgcacgg gcacctccag tggaaatcaa      300

gtgaacctca ctatccaagg actgagggcc atggacacgg gactctacat ctgcaaggtg      360

gagctcatgt acccaccgcc atactacgag ggcataggca acggaaccca gatttatgta      420

attgatccag aaccgtgccc agattctgat caggagccca aatcttctga caaaactcac      480

acatccccac cgtccccagc acctgaactc ctggggggat cgtcagtctt cctcttcccc      540

ccaaaaccca aggacaccct catgatctcc cggacccctg aggtcacatg cgtggtggtg      600

gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg      660

cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc      720

gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc      780

aacaaagccc tcccagcccc catcgagaaa accatctcca aagccaaagg gcagccccga      840

gaaccacagg tgtacaccct gcccccatcc cgggatgagc tgaccaagaa ccaggtcagc      900

ctgacctgcc tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat      960

gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc     1020

ttcctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca     1080

tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtct     1140

ccgggtaaat ga                                                         1152


<210>  2
<211>  383
<212>  PRT
<213>  Artificial

<220>
<223>  L104EA29YIg

<400>  2

Met Gly Val Leu Leu Thr Gln Arg Thr Leu Leu Ser Leu Val Leu Ala 
1               5                   10                  15      


Leu Leu Phe Pro Ser Met Ala Ser Met Ala Met His Val Ala Gln Pro 
            20                  25                  30          


Ala Val Val Leu Ala Ser Ser Arg Gly Ile Ala Ser Phe Val Cys Glu 
        35                  40                  45              


Tyr Ala Ser Pro Gly Lys Tyr Thr Glu Val Arg Val Thr Val Leu Arg 
    50                  55                  60                  


Gln Ala Asp Ser Gln Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met 
65                  70                  75                  80  


Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser Ile Cys Thr Gly Thr Ser 
                85                  90                  95      


Ser Gly Asn Gln Val Asn Leu Thr Ile Gln Gly Leu Arg Ala Met Asp 
            100                 105                 110         


Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr 
        115                 120                 125             


Tyr Glu Gly Ile Gly Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu 
    130                 135                 140                 


Pro Cys Pro Asp Ser Asp Gln Glu Pro Lys Ser Ser Asp Lys Thr His 
145                 150                 155                 160 


Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Ser Ser Val 
                165                 170                 175     


Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 
            180                 185                 190         


Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 
        195                 200                 205             


Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 
    210                 215                 220                 


Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 
225                 230                 235                 240 


Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 
                245                 250                 255     


Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 
            260                 265                 270         


Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 
        275                 280                 285             


Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 
    290                 295                 300                 


Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 
305                 310                 315                 320 


Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 
                325                 330                 335     


Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 
            340                 345                 350         


Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 
        355                 360                 365             


His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
    370                 375                 380             


